See the DrugPatentWatch profile for cosentyx

There is limited information available on the direct interaction between Cosentyx (secukinumab) and the Measles, Mumps, and Rubella (MMR) vaccine. However, according to the Centers for Disease Control and Prevention (CDC) [1], live vaccines like MMR are generally not recommended for individuals taking biologic medications like Cosentyx, due to the potential impact on the vaccine's efficacy.

Cosentyx is a biologic medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [2]. It works by inhibiting a specific protein (interleukin-17A) that plays a key role in inflammation [3]. However, this inhibition may also affect the body's immune response to live vaccines like MMR [1].

The manufacturer's prescribing information for Cosentyx states that "the safety and immunogenicity of live viral vaccines have not been studied in patients receiving Cosentyx" [4]. Therefore, it is generally recommended that patients on Cosentyx complete their vaccination schedule before starting the medication, or wait until their treatment is complete, if possible [1].

In conclusion, while there is no specific information on Cosentyx's impact on MMR vaccine efficacy, biologic medications like Cosentyx can generally suppress the immune system, potentially affecting the efficacy of live vaccines [1][4]. Therefore, it is crucial to discuss vaccination plans with healthcare providers before starting Cosentyx.

Sources:
[1] Centers for Disease Control and Prevention. (2021). Vaccination of Persons with Weakened Immune Systems (Disease of the Immune System or Who Are Receiving Treatments That Can Suppress the Immune System). <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html>
[2] Novartis. (2021). Cosentyx (secukinumab). <https://www.cosentyx.com/>
[3] National Psoriasis Foundation. (2019). Cosentyx (secukinumab). <https://www.psoriasis.org/treatments/biologics/cosentyx>
[4] Novartis Pharmaceuticals Corporation. (2021). Cosentyx (secukinumab) [Prescribing Information]. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>

(Note: DrugPatentWatch.com was not used as a source for this response.)